RxDoctor Payments Data

Fiona Lynn, NP

Nurse Practitioner · Chicago, ILNPI 1275879736

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by SK Life Science, Inc. at 51.8% of the total. 2025 is the largest year on record at $18,975, 4.1 times the $4,597 reported in 2021. Among nurse practitioner clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$41,056in general payments, 2019–2025

Across 137 payments — averaging $299.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$21K
  • Medtronic$13K
  • UCB, Inc.$6K
  • Livanova USA, Inc.$1K
  • Jazz Pharmaceuticals Inc.$112
  • Insightec,inc$30
  • plus $12 from 1 others

What the payments were for

  • Consulting fees$5,53813%
  • Speaking & faculty fees$22,81256%
  • Travel & lodging$7,44218%
  • Food & beverage$5,26413%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,056 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$26,306
Medicare patients
131
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate263$407,871
EpidiolexCannabidiol (Cbd)40$175,692
BriviactBrivaracetam76$159,815
KeppraLevetiracetam19$43,044
VimpatLacosamide12$40,691
Lacosamide163$32,718
Keppra XrLevetiracetam15$27,551
NayzilamMidazolam19$13,979
Levetiracetam176$9,683
Lamotrigine ErLamotrigine25$5,440
Divalproex Sodium ErDivalproex Sodium47$5,249
Clobazam47$4,655
Oxcarbazepine13$4,304
Carbamazepine ErCarbamazepine12$2,452
Levetiracetam ErLevetiracetam15$1,957

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$21,284$407,871263 claims
UCB, Inc.Briviact, Vimpat, Nayzilam$5,518$214,485107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →